Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Ayumi FujimotoRitsuro Suzuki

Abstract

We analyzed data from 64,539 consecutive patients in the Japanese national transplant registry, including 40,195 after allogeneic hematopoietic stem cell transplantation (HSCT), 24,215 after autologous HSCT and 129 after syngeneic HSCT, of whom 299 developed Epstein-Barr virus-positive post-transplant lymphoproliferative disorder (PTLD). The probability of developing PTLD at 2 years post-HSCT was .79% after allogeneic transplantation, .78% after syngeneic transplantation, and .11% after autologous transplantation. The following variables were identified as risk factors after allogeneic HSCT in multivariate analysis: antithymocyte globulin (ATG) use in a conditioning regimen, ATG use for acute graft-versus-host disease (GVHD) treatment, donor other than an HLA-matched related donor, aplastic anemia, second or subsequent allogeneic HSCT, the most recent year of transplantation, and acute GVHD. The probability at 2 years increased particularly after 2009 (1.24%) than before 2009 (.45%). To stratify the risk of PTLD before allogeneic HSCT, we developed a novel 5-point scoring system based on 3 pretransplant risk factors: ATG use in a conditioning regimen (high dose, 2 points; low dose, 1 point), donor type (HLA-mismatched related d...Continue Reading

Citations

Jan 19, 2020·Hematological Oncology·Ayumi FujimotoUNKNOWN Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation
Apr 29, 2020·International Journal of Hematology·Kentaro MizuharaYoshinobu Maeda
May 31, 2020·International Journal of Hematology·Masatomo KunoTakahiro Fukuda
Aug 12, 2020·Bone Marrow Transplantation·Ayumi FujimotoRitsuro Suzuki
Oct 13, 2020·Frontiers in Immunology·Francesca CompagnoPatrizia Comoli
Oct 29, 2020·Pediatric Transplantation·Cal H RobinsonVikas R Dharnidharka
Feb 7, 2021·Annals of Hematology·Francesco Pegoraro, Claudio Favre
Jan 19, 2021·Seminars in Nuclear Medicine·Hong SongAndrei Iagaru
Oct 1, 2020·Expert Review of Hematology·Andrea BacigalupoLivio Pagano
Feb 2, 2021·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Akiko YamadaAkihiko Gotoh
Aug 19, 2021·Best Practice & Research. Clinical Haematology·Andrea Bacigalupo, Giulia Benintende
Aug 29, 2021·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Julian LindsayMonica A Slavin
Nov 10, 2021·Current Opinion in Infectious Diseases·Julian LindsayMonica A Slavin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.